TSE:4502Pharmaceuticals
Takeda Pediatric ENTYVIO Data Adds New Angle To Growth Story
Takeda Pharmaceutical (TSE:4502) reported positive Phase 3 trial results for ENTYVIO in children and adolescents with ulcerative colitis.
The company plans to submit these data to regulators in major global markets for potential pediatric labeling expansion.
For Takeda, ENTYVIO sits at the core of its gastroenterology franchise, alongside a broader focus on specialty care and rare diseases. Positive pediatric data in ulcerative colitis speak directly to an area where treatment options are...